The success story behind Glenmark


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
The story begins in 1977. Saldanha starts a pharmaceutical company named after his two sons - Glenn and Mark. This is the beginning of a global pharmaceutical company - Glenmark Pharmaceuticals.

After a Master’s degree in Science from Bombay University and a Diploma in Management Studies from Jamnalal Bajaj Institute, Gracias Saldanha was equipped with theoretical knowledge. He acquired practical knowledge by working in multiple pharmaceutical companies for over 12 years. With all his learnings he decided to chart his own course. 

So the story begins in 1977. Saldanha starts a pharmaceutical company named after his two sons - Glenn and Mark. This is the beginning of a global pharmaceutical company - Glenmark Pharmaceuticals. The venture started with an initial investment of Rs 1 lakh and just three employees. Initially, the company heavily focuses on the new chemical entity (NCE) and a new biological entity (NBE). 

After two years of inception, they enter the dermatological market with their famous Candid Cream. Later in 1985, the company launched another product that captured the market named Ascoril. They then placed greater emphasis on R&D and opened a department in Nashik in 1987. Two years later they started their operations in multiple countries including Mauritius, Kenya, Afghanistan and more. 

In 1998, Glenn took the reins of the company from his father. He proved his worth and within 8 years the company recorded a ten-fold growth. The company now had operations in 80 countries and had a turnover of $7.5 billion. One thing his MBA from New York University had taught him was the value of research. Despite the cynicism of investors at the time, Glenmark spent 8% of company revenue on R&D, a number unheard of within the industry. 

By 2008, Glenmark was the fifth biggest pharmaceutical company in India. By 2011, the founder became the richest man solely because the company entered the USA and European markets. In 2015, the Cabinet Committee on Economic Affairs agreed on the foreign investment proposal worth Rs 4187 crore for two pharmaceutical companies, one of which was Glenmark. 

In 2017, the companies total income was Rs 8243.74 crores. But the number declined to Rs 6780.48 crores by 2019. Since the pandemic, the company has again seen a steady rise. Their total income in 2020 was Rs 7319.42 crores and this year it was Rs 7964.17 crores. At the CSR Summit 2019, the company was honoured with ‘CSR Foundation of the Year Award’.

Tags : #Glenmark #GraciasSaldanha #GlennSaldanha #Indiapharmacy #pharmaceuticals #success #startup #smitakumar #medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026